Trials / No Longer Available
No Longer AvailableNCT05503550
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
Pre-Approval Access Single Patient Request Treatment for Talquetamab for Treating Physician Use in Relapsed or Refractory Multiple Myeloma
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- —
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Talquetamab | Talquetamab will be administered subcutaneously (SC). |
Timeline
- First posted
- 2022-08-16
- Last updated
- 2025-12-16
Source: ClinicalTrials.gov record NCT05503550. Inclusion in this directory is not an endorsement.